Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants

2.

Getting More Done With Less Blood.

3.

New analysis helps discern benign from malignant thyroid growths

4.

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.

5.

Children living near oil and gas wells face higher risk of rare leukemia, studies show


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot